Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...
If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...
A chronic and progressive neurological condition that affects millions across the world, multiple sclerosis (MS ... This is ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Raritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Legendary folk singer Sharda Sinha, known for her Chhath songs has died at the age of 72 years. The Padma Bhushan awardee was ...
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other ...
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...
From yoga and gym four times a week to hospital wards and chemotherapy, Hamiltonian Amanda Shanley, 60, never imagined she’d ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback